



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

12th November 2021
IOLCP/CGC/2021

National Stock Exchange of India Ltd

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400 001

Security Symbol: IOLCP

Security Code: 524164

Subject: Press Release with respect to Audited Financial Results for the quarter and half year ended 30th September 2021.

Dear Sir,

Please find enclosed herewith Press Release with respect to Audited Financial Results for the quarter and half year ended 30th September 2021.

The Press Release is also available on the website of the Company i.e. www.iolcp.com.

This is for your information & record.

Thanking You,

Yours faithfully,
For IOL Chemicals and Pharmaceuticals Limited


Abhay Raj Singh
Vice President & Company Secretary





Press Release

12th November 2021, Ludhiana

IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of pharmaceutical (APIs) and specialty chemicals today posted its financial results for the quarter and half year ending 30th September 2021. The Company on QoQ basis recorded 5% growth in total income, however the EBITDA has been declined by about 53% on QoQ basis.

September 2021 vis a vis June 2021:

Rs Crore

Particulars	Quarter ended	
	30.09.2021	30.06.2021
Total income	548	524
EBIDTA	54	116
Profit before Tax	42	90
Profit after Tax	31	67

Dr Sanjay Chaturvedi, Chief Executive Officer said "During the quarter ended September 2021, the Company's performance has been muted presently due to contraction in flagship API demand and volatility in raw material prices of Chemical products.

He further stated that revenue from new products in pharma API has been getting positive response.

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Company was established in 1986, listed on National Stock Exchange of India Ltd (Code: IOLCP) and BSE Ltd (Code: 524164) is one of the leading pharmaceutical (APIs) Company and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, anti-convulsants, anti-diabetes, anti- cholesterol and anti-platelets.

The Company's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.

Company is World's largest producer of the Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR approved R&D which is fully equipped to validate existing processes.



The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with Zero Liquid Discharge (ZLD) system alongwith 17 MW captive Co-Generation plant for self reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including UK, Austria, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Portugal, Poland, Ireland, USA, Australia, Chile, Peru, Brazil, Argentina, Colombia, Mexico, Indonesia, South Korea, Thailand etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

Disclaimer:

This document may contain statement which reflect management's current views and estimates and could be construed as forward looking statements. The future involves certain risks and uncertainties, and could cause actual results to differ materially for the current views being expressed. Potential risks and uncertainties include factors as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.

